On a roll, Regeneron and Sanofi boast positive PhIII OS results in 'notoriously' tough cancer
As the sixth checkpoint inhibitor on the US market, Regeneron and Sanofi’s Libtayo has claimed quite a few firsts. And they can now add one more feather to their PD-1 cap.
The companies revealed early Monday that they’re stopping a Phase III cervical cancer trial early after Libtayo was shown to cut the risk of death by 31% over chemotherapy, paving way for regulatory submissions later this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.